American College of Genetic and Genomics Jul 28 2016
BETHESDA, MD – July 28, 2016 | Noninvasive prenatal screening using cell-free placental DNA circulating in maternal blood (NIPS) has been rapidly integrated into prenatal care since the American College of Medical Genetics and Genomics (ACMG) released its 2013 Position Statement on its use. “New data and provider and patient demand required an updated ACMG position on the use of NIPS in prenatal care,” said lead author of the ACMG statement and high-risk pregnancy physician, Anthony R. Gregg, MD, MBA, FACOG, FACMG. “We provide a framework for understanding how genetic technology moves from an idea into clinical practice. ACMG continues to stress that NIPS is a screening rather than a diagnostic test and positive results should be followed by a diagnostic test such as chorionic villus sampling or amniocentesis.”(Diagnostic tests eliminate the problem of false positive and false negative results associated with a screening test).